1079 related articles for article (PubMed ID: 14672345)
1. Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture.
Lane NE; Yao W; Kinney JH; Modin G; Balooch M; Wronski TJ
J Bone Miner Res; 2003 Dec; 18(12):2105-15. PubMed ID: 14672345
[TBL] [Abstract][Full Text] [Related]
2. Sequential treatment with basic fibroblast growth factor and parathyroid hormone restores lost cancellous bone mass and strength in the proximal tibia of aged ovariectomized rats.
Wronski TJ; Ratkus AM; Thomsen JS; Vulcan Q; Mosekilde L
J Bone Miner Res; 2001 Aug; 16(8):1399-407. PubMed ID: 11499862
[TBL] [Abstract][Full Text] [Related]
3. Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats.
Lane NE; Thompson JM; Strewler GJ; Kinney JH
J Bone Miner Res; 1995 Oct; 10(10):1470-7. PubMed ID: 8686502
[TBL] [Abstract][Full Text] [Related]
4. Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.
Iwaniec UT; Mosekilde L; Mitova-Caneva NG; Thomsen JS; Wronski TJ
Endocrinology; 2002 Jul; 143(7):2515-26. PubMed ID: 12072383
[TBL] [Abstract][Full Text] [Related]
5. Bone-selective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model.
Lane NE; Kimmel DB; Nilsson MH; Cohen FE; Newton S; Nissenson RA; Strewler GJ
J Bone Miner Res; 1996 May; 11(5):614-25. PubMed ID: 9157776
[TBL] [Abstract][Full Text] [Related]
6. Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model.
Lane NE; Kumer J; Yao W; Breunig T; Wronski T; Modin G; Kinney JH
Osteoporos Int; 2003 Jun; 14(5):374-82. PubMed ID: 12768279
[TBL] [Abstract][Full Text] [Related]
7. Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats.
McManus JF; Davey RA; Maclean HE; Doust EA; Chiu WS; Sims NA; Bouxsein ML; Glatt V; Zajac JD; Danks JA
Bone; 2008 Jun; 42(6):1164-74. PubMed ID: 18387351
[TBL] [Abstract][Full Text] [Related]
8. Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization.
Yao W; Balooch G; Balooch M; Jiang Y; Nalla RK; Kinney J; Wronski TJ; Lane NE
Bone; 2006 Sep; 39(3):460-9. PubMed ID: 16713415
[TBL] [Abstract][Full Text] [Related]
9. Basic fibroblast growth factor improves trabecular bone connectivity and bone strength in the lumbar vertebral body of osteopenic rats.
Yao W; Hadi T; Jiang Y; Lotz J; Wronski TJ; Lane NE
Osteoporos Int; 2005 Dec; 16(12):1939-47. PubMed ID: 16086094
[TBL] [Abstract][Full Text] [Related]
10. Early estrogen replacement therapy reverses the rapid loss of trabecular bone volume and prevents further deterioration of connectivity in the rat.
Lane NE; Haupt D; Kimmel DB; Modin G; Kinney JH
J Bone Miner Res; 1999 Feb; 14(2):206-14. PubMed ID: 9933474
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats.
Rhee Y; Won YY; Baek MH; Lim SK
J Bone Miner Res; 2004 Jun; 19(6):931-7. PubMed ID: 15125792
[TBL] [Abstract][Full Text] [Related]
12. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
Shen V; Birchman R; Wu DD; Lindsay R
J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
[TBL] [Abstract][Full Text] [Related]
13. Human parathyroid hormone-(1-38) restores cancellous bone to the immobilized, osteopenic proximal tibial metaphysis in rats.
Ma YF; Jee WS; Ke HZ; Lin BY; Liang XG; Li M; Yamamoto N
J Bone Miner Res; 1995 Mar; 10(3):496-505. PubMed ID: 7785472
[TBL] [Abstract][Full Text] [Related]
14. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
[TBL] [Abstract][Full Text] [Related]
15. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats.
Kimmel DB; Bozzato RP; Kronis KA; Coble T; Sindrey D; Kwong P; Recker RR
Endocrinology; 1993 Apr; 132(4):1577-84. PubMed ID: 8462456
[TBL] [Abstract][Full Text] [Related]
16. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine.
Fox J; Miller MA; Newman MK; Turner CH; Recker RR; Smith SY
J Bone Miner Res; 2007 Feb; 22(2):260-73. PubMed ID: 17087625
[TBL] [Abstract][Full Text] [Related]
17. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of exercise and propranolol on bone tissue in ovariectomized rats.
Bonnet N; Beaupied H; Vico L; Dolleans E; Laroche N; Courteix D; Benhamou CL
J Bone Miner Res; 2007 Apr; 22(4):578-88. PubMed ID: 17243867
[TBL] [Abstract][Full Text] [Related]
19. Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats.
Dresner-Pollak R; Gabet Y; Steimatzky A; Hamdani G; Bab I; Ackerman Z; Weinreb M
Gastroenterology; 2008 Jan; 134(1):259-67. PubMed ID: 18061175
[TBL] [Abstract][Full Text] [Related]
20. Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats.
Bonnet N; Laroche N; Vico L; Dolleans E; Benhamou CL; Courteix D
J Pharmacol Exp Ther; 2006 Sep; 318(3):1118-27. PubMed ID: 16740619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
